{"id":898744,"date":"2025-10-22T08:32:11","date_gmt":"2025-10-22T12:32:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/"},"modified":"2025-10-22T08:32:11","modified_gmt":"2025-10-22T12:32:11","slug":"equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/","title":{"rendered":"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025"},"content":{"rendered":"<h2>\nVirtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">LA JOLLA, Calif., Oct.  22, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xj3T9KWfW7iv3DcApbTsA6fbfAXefPRmZJaxRRPF3D-9NJcVmaQYWk6glVIc1Id0ZCx_eZXtb8A1UyXfBJ11WXouFwmsRK3EZFMY_X9JDJvR8WnpPu9sEEX36PXMkyW3\" rel=\"nofollow\" target=\"_blank\"><u>Equillium<\/u><\/a>, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced they will host a virtual key opinion leader (KOL) event on Wednesday, November 5, 2025, at 12:00 PM ET.<\/p>\n<p align=\"left\">The event will feature experts in their fields, Francisco J. Quintana, PhD (Harvard Medical School) and Brian Feagan, MD, FRCPC (Western Ontario), who will discuss the unmet needs and evolving treatment landscape in ulcerative colitis (UC) and the promise of targeting AhR to resolve inflammation and promote mucosal healing in this chronic inflammatory disease.<\/p>\n<p align=\"left\">Company management will also provide a scientific and translational overview of EQ504, Equillium\u2019s potent oral, colon-targeted AhR modulator that\u00a0selectively activates key anti-inflammatory and tissue-regenerative pathways. Presenters will review preclinical data demonstrating EQ504\u2019s differentiated mechanism of action \u2013 enhancing IL-10 and IL-22 signaling, driving regulatory T-cell function, and protecting epithelial barrier integrity \u2013 and discuss the company\u2019s plans for a Phase 1 proof-of-mechanism study expected to initiate mid-2026.<\/p>\n<p align=\"left\">A live question-and-answer session will follow the formal presentations. To register for the event, please click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l_Lx7Zt2XAAtOAPr_fYQBP8IUwP7RsAsEQtuYQLDP6QiJ79jGeGco172X1xRjUieKnG9st1kwHeFeO7kwhnwWBxlhWG80NP5_UROPnKJZJw=\" rel=\"nofollow\" target=\"_blank\"><u>here<\/u><\/a>. A replay of the webinar will be accessible in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WmGZ9Y7duOEfmfrqjzr_Mk7orLVznAzUCWQGsi8NfChub4AGJyU0lFZxQFqlEqykuuf8lXcuk_WxDCbYqABQ-YJGF6a6z4G4EBecqpKXykWXjrk3fI1NkrQkXkeUWe_x6GoMGr7_fhNXfhRicZlvNA==\" rel=\"nofollow\" target=\"_blank\"><u>Investors section<\/u><\/a> of Equillium\u2019s website following the event.<\/p>\n<p align=\"left\">\n        <strong>About Equillium <\/strong><br \/>\n        <br \/>Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company\u2019s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.<\/p>\n<p align=\"left\">For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1vMo16GKDBcWoAQSc5D3I0WPIriOMlTsv1PDU4S1UuxNHDqNd9y9-H3GLcFkgUqgj7ZjoSEKFGqfWLIV0bjEJqY4G11B5PWGSqtdzYUxDJpunFbtPREqOjilfUTmMsrX\" rel=\"nofollow\" target=\"_blank\"><u>www.equilliumbio.com<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>PJ Kelleher<br \/>LifeSci Advisors, LLC<br \/>+1-617-430-7579<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UeGDmfq4_yHFLmVztVGMZLTMkiRTKt9h-Jnq_rse6s0bipoT3CPbaRyjL2yE_p3eaRNxvZ_tUn-ji7nXZqVllgGULAux_Tj_k5DSVwZIwK8CRFeRaCvNKhXRVnOofEd8M9nAwERLjxFJLVCcxyvfyrgtLrcVf9Q1sDbT9Yay_geF1B-nS3BVfvpDK7XLe_8pWkByWZJFjgA_6cepDRx6LlMsuQ0fuQrMGJkQkchL7hzINlcdrviUD9rZ6Z9NjCeMlnSvhmvLUPFyjOPhPF_0mo5OljtwXKQMBoHqt8U4Y0X8VRrypmjKmdFlgJ6AaGED\" rel=\"nofollow\" target=\"_blank\"><u>pkelleher@lifesciadvisors.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Njk1N2NmN2ItNTE5Ny00ZDhkLTgzZjctZWZhNDYyNmJmZTgzLTUwMDE1Mjg5Ni0yMDI1LTEwLTIyLWVu\/tiny\/Equillium-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis LA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced they will host a virtual key opinion leader (KOL) event on Wednesday, November 5, 2025, at 12:00 PM ET. The event will feature experts in their fields, Francisco J. Quintana, PhD (Harvard Medical School) and Brian Feagan, MD, FRCPC (Western Ontario), who will discuss the unmet needs and evolving treatment landscape in ulcerative colitis (UC) and the promise of targeting &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898744","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis LA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced they will host a virtual key opinion leader (KOL) event on Wednesday, November 5, 2025, at 12:00 PM ET. The event will feature experts in their fields, Francisco J. Quintana, PhD (Harvard Medical School) and Brian Feagan, MD, FRCPC (Western Ontario), who will discuss the unmet needs and evolving treatment landscape in ulcerative colitis (UC) and the promise of targeting &hellip; Continue reading &quot;Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T12:32:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025\",\"datePublished\":\"2025-10-22T12:32:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/\"},\"wordCount\":306,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/\",\"name\":\"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng==\",\"datePublished\":\"2025-10-22T12:32:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/","og_locale":"en_US","og_type":"article","og_title":"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - Market Newsdesk","og_description":"Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis LA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced they will host a virtual key opinion leader (KOL) event on Wednesday, November 5, 2025, at 12:00 PM ET. The event will feature experts in their fields, Francisco J. Quintana, PhD (Harvard Medical School) and Brian Feagan, MD, FRCPC (Western Ontario), who will discuss the unmet needs and evolving treatment landscape in ulcerative colitis (UC) and the promise of targeting &hellip; Continue reading \"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-22T12:32:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025","datePublished":"2025-10-22T12:32:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/"},"wordCount":306,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/","name":"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng==","datePublished":"2025-10-22T12:32:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTgzOCM3MjA4MjY4IzUwMDE1Mjg5Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-host-ulcerative-colitis-kol-event-on-november-5-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898744"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898744\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}